Norwegian Cruise Line Holdings Reports Financial Results for the Second Quarter 2017
Aug 08, 2017 11:01 am UTC| Business
Company Reports Record Second Quarter Earnings Per Share, with Growth of 36% Strong Operating Environment and Revenue Initiatives Result in Increase of Full Year Guidance Company’s Newest Ship, Norwegian Joy, Christened...
uniQure Announces Second Quarter 2017 Financial Results and Recent Company Progress
Aug 08, 2017 11:01 am UTC| Business
~ Advancing Gene Therapy Programs in Hemophilia B and Huntington’s Disease ~~ Provides Update on Research Collaboration with Bristol-Myers Squibb ~~ Makes New Appointments to Company Leadership and Nominations to Board of...
Karyopharm Reports Second Quarter 2017 Financial Results and Highlights Recent Progress
Aug 08, 2017 11:01 am UTC| Business
− Pivotal Phase 3 BOSTON Study Underway – − Updated Phase 1b/2 STOMP Data Expected by Year End 2017; Top-line Phase 2b STORM Data Expected by April 2018 – − Phase 2 SEAL Hazard Ratio Expected in September/October 2017,...
Aug 08, 2017 11:01 am UTC| Business
THE WOODLANDS, Texas, Aug. 08, 2017 -- LGI Homes, Inc. (Nasdaq:LGIH) today announced results for the second quarter 2017 and the six months ended June 30, 2017. Second Quarter 2017 Results and Comparisons to Second...
Plug Power Announces 2017 Second Quarter Results
Aug 08, 2017 11:01 am UTC| Business
LATHAM, N.Y., Aug. 08, 2017 -- Plug Power Inc. (NASDAQ:PLUG), a leader in providing energy solutions that change the way the world moves, announced today its 2017 second quarter results. The quarterly Shareholder Letter...
Aclaris Therapeutics Reports Second Quarter 2017 Financial Results
Aug 08, 2017 11:01 am UTC| Business
MALVERN, Pa., Aug. 08, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced financial results for the second quarter of 2017 and provided an update on its...
Agios Reports Second Quarter 2017 Financial Results
Aug 08, 2017 11:01 am UTC| Business
– IDHIFA® (enasidenib) Granted Approval from FDA as First Targeted Therapy for Patients with IDH2m R/R AML and First Product Approved from Agios’ Discovery Platform – – Trial Designs Finalized for Two Pivotal Studies for...